Vikram S Kashyap, co-principal investigator of the ROADSTER 2 trial, today presented the final 30-day outcomes of the post-market approval study in a late-breaking trial session at the Society for Vascular Surgery (SVS) Vascular Annual Meeting (VAM; 12–15 June, National Harbor, USA). The data show the sustained safety and efficacy of transcarotid artery revascularisation (TCAR) with Silk Road Medical’s Enroute system. In this interview, Kashyap speaks to Vascular News about the procedure, and how TCAR trialists are hoping to make an impact for patients needing carotid revascularisation.
What is the idea behind TCAR, and how does it differ from carotid endarterectomy or transfemoral carotid stenting?
Transcarotid artery revascularisation is very different to other treatment strategies, such as carotid endarterectomy [CEA] or stenting [CAS]. This is a carotid stenting procedure, but it is via a different approach—a transcarotid approach—and the critical issue is that there is a protection mechanism to prevent cerebral embolisation which is using an extracorporeal reversal flow system, and importantly, clamping of the carotid artery below the sheath insertion that leads to obligate reversal flow in the carotid system during the intervention. So, this is very different to transfemoral CAS in that one does not have to navigate the aortic arch and the carotid arteries to get the devices there.
Read More: https://vascularnews.com/final-results-of-the-roadster-2-post-market-approval-study-of-tcar-interview-with-vikram-s-kashyap/